Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Scully

Showing results (71-80 of 159) with videos related to

Pageof 16
Sort By:
British Journal of Haematology|October 22, 2020
Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpuraFerras Alwan, Dina Mahdi, Sarrah Tayabali, et al.
Journal of the Intensive Care Society|June 4, 2020
Extra-corporeal membrane oxygenation and Eculizumab: Atypical treatments for typical haemolytic uraemic syndromeMatthew D Kelham, Liam Gleeson, Inma Alcalde, et al.
Blood Advances|June 12, 2026
Delayed ADAMTS13 normalisation in caplacizumab/PEX treated patients associated with anti-ADAMTS13 IgG antibody boostingNithya Prasannan, Arshia Latif, John-Paul Westwood, et al.
Ejhaem|September 2, 2022
Unmet needs in the management of immune-mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK-A modified-Delphi studyMarie Scully, Tina Dutt, Will Lester, et al.
Thrombosis and Haemostasis|January 12, 2013
Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathiesIan Mackie, Katy Langley, Andrew Chitolie, et al.
Journal of Thrombosis and Haemostasis : JTH|February 15, 2026
Caplacizumab resistance in immune thrombotic thrombocytopenic purpura (iTTP) associated with VWF A1 domain missense variantMari Thomas, Imogen Buckle, Adela Constantinescu-Bercu, et al.
Blood|January 31, 2023
Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab eraNithya Prasannan, Mari Thomas, Matthew Stubbs, et al.
Journal of Thrombosis and Haemostasis : JTH|May 11, 2021
Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccinationSean Platton, Andrew Bartlett, Peter MacCallum, et al.
Ejhaem|July 18, 2022
Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpuraFerras Alwan, Chiara Vendramin, Ulrich Budde, et al.
Transfusion|April 22, 2024
Thirty years of experience with solvent/detergent-treated plasma for transfusion medicineSabrina E Racine-Brzostek, Melissa M Cushing, Michelle Gareis, et al.
Pageof 16

Showing results (71-80 of 159) with videos related to

Sort By:
Pageof 16
British Journal of Haematology|October 22, 2020
Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpuraFerras Alwan, Dina Mahdi, Sarrah Tayabali, et al.
Journal of the Intensive Care Society|June 4, 2020
Extra-corporeal membrane oxygenation and Eculizumab: Atypical treatments for typical haemolytic uraemic syndromeMatthew D Kelham, Liam Gleeson, Inma Alcalde, et al.
Blood Advances|June 12, 2026
Delayed ADAMTS13 normalisation in caplacizumab/PEX treated patients associated with anti-ADAMTS13 IgG antibody boostingNithya Prasannan, Arshia Latif, John-Paul Westwood, et al.
Ejhaem|September 2, 2022
Unmet needs in the management of immune-mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK-A modified-Delphi studyMarie Scully, Tina Dutt, Will Lester, et al.
Thrombosis and Haemostasis|January 12, 2013
Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathiesIan Mackie, Katy Langley, Andrew Chitolie, et al.
Journal of Thrombosis and Haemostasis : JTH|February 15, 2026
Caplacizumab resistance in immune thrombotic thrombocytopenic purpura (iTTP) associated with VWF A1 domain missense variantMari Thomas, Imogen Buckle, Adela Constantinescu-Bercu, et al.
Blood|January 31, 2023
Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab eraNithya Prasannan, Mari Thomas, Matthew Stubbs, et al.
Journal of Thrombosis and Haemostasis : JTH|May 11, 2021
Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccinationSean Platton, Andrew Bartlett, Peter MacCallum, et al.
Ejhaem|July 18, 2022
Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpuraFerras Alwan, Chiara Vendramin, Ulrich Budde, et al.
Transfusion|April 22, 2024
Thirty years of experience with solvent/detergent-treated plasma for transfusion medicineSabrina E Racine-Brzostek, Melissa M Cushing, Michelle Gareis, et al.
Pageof 16